Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT06285019
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Rectal CancerNeoadjuvant Therapy
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 198
- Registration Number
- NCT06281405
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Effectiveness of Gut Microbiota-targeted Dietary Intervention Among HIV-infected Patients
Not Applicable
Not yet recruiting
- Conditions
- HivDiet, HealthyCardiovascular Diseases
- Interventions
- Dietary Supplement: gut microbiota-targeted dietary intervention
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 106
- Registration Number
- NCT06279819
- Locations
- 🇨🇳
Fudan University, Shanghai, Shanghai, China
Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques
Not Applicable
Not yet recruiting
- Conditions
- Pain, PostoperativeGastrointestinal TumorsSurgical Wound Infection
- Interventions
- Procedure: Non-Dressing of Surgical WoundProcedure: Regular Dressing Change of Surgical Wound
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 816
- Registration Number
- NCT06263205
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Not Applicable
Not yet recruiting
- Conditions
- Small Cell Lung Cancer Recurrent
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 39
- Registration Number
- NCT06258642
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
A Study on the Prognosis of Two Different Surgery Methods in Patients With Rectal Endometriosis
Recruiting
- Conditions
- Gastrointestinal FunctionQuality of LifePregnancy Outcomes
- Interventions
- Procedure: disc resectionProcedure: segmental resection
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 90
- Registration Number
- NCT06254716
- Locations
- 🇨🇳
OB & GYN Hospital of Fudan University, Shanghai, Shanghai, China
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
Phase 3
Recruiting
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Drug: Gemcitabine, Nab-paclitaxel, IrinotecanRadiation: Intensity-Modulated Radiation Therapy (IMRT)
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 210
- Registration Number
- NCT06250972
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Phase 2
Recruiting
- Conditions
- Prostate Cancer MetastaticCastration-resistant Prostate Cancer
- Interventions
- Radiation: Stereotactic body radiotherapy
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06251492
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center Xiamen Branch., Xiamen, Fujian, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
Phase 2
Recruiting
- Conditions
- Pancreatic CancerRadiotherapy
- Interventions
- Drug: mFOLFIRINOX plus IMRT
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06249321
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Other: Blood collection
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 168
- Registration Number
- NCT06249308
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath